Fate Therapeutics Inc.
FATE | NASDAQ
$2.62
+$0.09 (+3.56%)
Sep 22, 2026, 12:52 PM ET · Market open
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 6.49M | 6.32M | 6.65M | 7.14M | 8.47M | 13.34M | 13.63M | 13.45M | 12.32M | 6.48M | 63.53M | 106.21M | 119.25M | 136.87M | 96.3M | 69.01M | 68.26M | 63.12M | 55.85M | 54.68M | 48.01M | 40.06M |
Cost of Revenue | 28.76M | 32.58M | 58.8M | 75.93M | 84.75M | 85.65M | 61.33M | 49.08M | 19.17M | 55.32M | 116.13M | 198.44M | 273.51M | 313.94M | 320.45M | 302.78M | 276.09M | 242.81M | 215.52M | 184.99M | 162.55M | 141.2M |
Gross Profit | -22.27M | -26.26M | -52.15M | -68.8M | -76.28M | -72.31M | -47.7M | -35.63M | -6.85M | -48.84M | -52.6M | -92.22M | -154.26M | -177.08M | -224.15M | -233.77M | -207.83M | -179.69M | -159.67M | -130.31M | -114.54M | -101.14M |
Operating Income | -133.59M | -139.42M | -147.7M | -174.73M | -192.37M | -200.49M | -210.28M | -196.6M | -195.51M | -212.99M | -190.51M | -206.86M | -241.97M | -262.51M | -308.39M | -313.35M | -281.58M | -245.25M | -216.99M | -181.01M | -157.88M | -139.8M |
Interest Income | 8.22M | 9.58M | 11.05M | 12.71M | 14.57M | 16.48M | 17.29M | 17.83M | 18.09M | 17.64M | 17.19M | 15.65M | 12.74M | 9.12M | 5.84M | 3.26M | 1.76M | 1.35M | 1.31M | 1.36M | 1.52M | 1.8M |
Pretax Income | -126M | -129.91M | -136.32M | -156.09M | -171.52M | -175.88M | -186.26M | -178.23M | -175.72M | -190.05M | -160.93M | -173.17M | -211.56M | -234.91M | -281.72M | -293.98M | -253.72M | -232.75M | -212.15M | -196.64M | -212.02M | -184.96M |
Net Income | -126M | -129.91M | -136.32M | -156.09M | -171.52M | -175.88M | -186.26M | -178.23M | -175.72M | -190.05M | -160.93M | -173.17M | -211.56M | -234.91M | -281.72M | -293.98M | -253.72M | -232.75M | -212.15M | -196.64M | -212.02M | -184.96M |
Selling & General & Admin | 39.73M | 42.34M | 46.52M | 67.59M | 77.75M | 83.56M | 90.64M | 76.84M | 74.99M | 80.36M | 81.45M | 85.1M | 87.7M | 85.43M | 84.23M | 79.58M | 73.75M | 65.56M | 57.32M | 50.7M | 43.33M | 38.67M |
Research & Development | 97.44M | 100.48M | 107.83M | 116.01M | 124.83M | 132M | 135M | 133.21M | 132.83M | 139.11M | 172.6M | 227.97M | 273.51M | 313.94M | 320.45M | 302.78M | 276.09M | 242.81M | 215.52M | 184.99M | 162.55M | 141.2M |
Other Expenses | -25.84M | -29.66M | -58.8M | -77.67M | -86.48M | -87.38M | -63.06M | -49.08M | -19.17M | -55.32M | -116.13M | -198.44M | -273.51M | -313.94M | -320.45M | -302.78M | -276.09M | -242.81M | -215.52M | -184.99M | -162.55M | -141.2M |
Operating Expenses | 111.33M | 113.16M | 95.56M | 105.93M | 116.1M | 128.18M | 162.58M | 160.97M | 188.66M | 164.14M | 137.91M | 114.63M | 87.7M | 85.43M | 84.23M | 79.58M | 73.75M | 65.56M | 57.32M | 50.7M | 43.33M | 38.67M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | 16.47M | 16.47M | 16.47M | 16.47M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 140.08M | 145.74M | 154.35M | 181.87M | 200.84M | 213.82M | 223.91M | 210.05M | 207.82M | 219.47M | 254.04M | 313.07M | 361.22M | 399.38M | 404.69M | 382.36M | 349.84M | 308.37M | 272.84M | 235.69M | 205.88M | 179.86M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 120.4M | 120.03M | 118.79M | 119M | 118.53M | 118.38M | 117.79M | 117.77M | 117.47M | 101.1M | 98.61M | 98.57M | 98.4M | 98.05M | 97.22M | 97.02M | 96.7M | 96.34M | 95.79M | 95.41M | 94.33M | 93.43M |
Shares Outstanding (Diluted) | 120.4M | 120.03M | 118.79M | 119M | 118.53M | 118.38M | 117.79M | 117.77M | 117.47M | 101.1M | 98.61M | 98.57M | 98.4M | 98.05M | 97.22M | 97.02M | 96.7M | 96.34M | 95.79M | 95.41M | 94.33M | 93.43M |
EPS (Basic) | -1.05 | -1.09 | -1.15 | -1.32 | -1.45 | -1.49 | -1.64 | -1.65 | -1.71 | -1.92 | -1.54 | -1.59 | -1.96 | -2.21 | -2.71 | -2.93 | -2.55 | -2.34 | -2.23 | -2.12 | -2.35 | -2.12 |
EPS (Diluted) | -1.05 | -1.09 | -1.15 | -1.32 | -1.45 | -1.49 | -1.64 | -1.65 | -1.71 | -1.92 | -1.54 | -1.59 | -1.96 | -2.21 | -2.71 | -2.93 | -2.55 | -2.34 | -2.23 | -2.12 | -2.35 | -2.12 |
EBITDA | -117.18M | -117.42M | -123.41M | -136.3M | -150.35M | -153.26M | -162.16M | -159.2M | -156.56M | -171.14M | -142.65M | -154.93M | -194.87M | -219.72M | -267.96M | -282.86M | -244.28M | -225.1M | -207.42M | -173.54M | -162.47M | -136.46M |
EBIT | -126.39M | -129.91M | -136.32M | -150.95M | -166.38M | -170.74M | -181.12M | -178.23M | -175.72M | -190.05M | -160.93M | -173.17M | -211.56M | -234.91M | -281.72M | -293.98M | -253.72M | -232.75M | -213.27M | -178.05M | -166.23M | -139.8M |
Depreciation & Amortization | 9.21M | 12.49M | 12.9M | 14.65M | 16.03M | 17.47M | 18.96M | 19.03M | 19.17M | 18.91M | 18.28M | 18.24M | 16.69M | 15.19M | 13.76M | 11.12M | 9.45M | 7.65M | 5.85M | 4.51M | 3.76M | 3.34M |
Add to Watchlist
Select watchlists to add or remove FATE